Vedolizumab induction and maintenance though levels and long-term clinical and biochemical status in inflammatory bowel disease

被引：0
|
作者：
Gutierrez Casbas, A. [1 ]
Sempere Robles, L. [2 ]
Munoz Perez, R. [2 ]
Rodriguez Angulo, A. [2 ]
Climent, S. [3 ]
Cameo Lorenzo, J. I. [2 ]
Diaz, M. [3 ]
Boada, P. [3 ]
Mas-Serrano, P. [3 ]
机构：
[1] Hosp Gen Univ Alicante, CIBERehd, Dept Gastroenterol, Alicante, Spain
[2] Hosp Gen Univ Alicante, Dept Gastroenterol, Alicante, Spain
[3] Hosp Gen Univ Alicante, Dept Pharm, Alicante, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P695
引用
收藏
页码：S563 / S564
页数：2
相关论文
共 50 条
  • [1] Can induction and maintenance serum vedolizumab levels predict long-term clinical outcome in inflammatory bowel disease (IBD)?
    Miller, C.
    Morgan, H.
    Steel, A.
    Wahed, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S413 - S414
  • [2] Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease
    Yarur, A.
    Bruss, A.
    Fox, C.
    Beniwal-Patel, P.
    Patel, A.
    Berens, B.
    Naik, S.
    Stein, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S64 - S65
  • [3] VEDOLIZUMAB LEVELS DURING INDUCTION ARE ASSOCIATED WITH LONG-TERM CLINICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Yarur, Andres J.
    Bruss, Alexandra
    Berens, Brandon
    Fox, Caroline
    Beniwal-Patel, Poonam M.
    Patel, Amir
    Ungaro, Ryan C.
    Dubinsky, Marla
    Naik, Snehal
    Stein, Daniel J.
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S827 - S828
  • [4] Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
    Parikh, Asit
    Fox, Irving
    Leach, Timothy
    Xu, Jing
    Scholz, Catherine
    Patella, Michael
    Feagan, Brian G.
    [J]. INFLAMMATORY BOWEL DISEASES, 2013, 19 (08) : 1691 - 1699
  • [5] Long-term safety of vedolizumab for inflammatory bowel disease
    Loftus, Edward V., Jr.
    Feagan, Brian G.
    Panaccione, Remo
    Colombel, Jean-Frederic
    Sandborn, William J.
    Sands, Bruce E.
    Danese, Silvio
    D'Haens, Geert
    Rubin, David T.
    Shafran, Ira
    Parfionovas, Andrejus
    Rogers, Raquel
    Lirio, Richard A.
    Vermeire, Severine
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (08) : 1353 - 1365
  • [6] Vedolizumab in the induction and maintenance of inflammatory bowel disease treatment
    Tebar Marquez, D.
    [J]. REVISTA CLINICA ESPANOLA, 2014, 214 (03): : 161 - 162
  • [7] ASSOCIATION OF VEDOLIZUMAB LEVELS WITH CLINICAL AND BIOCHEMICAL MARKERS OF INFLAMMATION DURING MAINTENANCE THERAPY IN INFLAMMATORY BOWEL DISEASE
    Plevris, Nikolas
    Jones, Gareth-Rhys
    Jenkinson, Philip
    Lyons, Mathew
    Merchant, Lynne M.
    Pattenden, Rebecca J.
    Arnott, Ian
    Lees, Charlie W.
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S1142 - S1142
  • [8] Association of vedolizumab levels with clinical and biochemical markers of inflammation during maintenance therapy in inflammatory bowel disease
    Plevris, N.
    Jones, G. R.
    Jenkinson, P. W.
    Chuah, C. S.
    Lyons, M.
    Merchant, L. M.
    Pattenden, R. J.
    Arnott, I. D.
    Lees, C. W.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S347 - S347
  • [9] Long-Term Efficacy of Vedolizumab in Pediatric Inflammatory Bowel Disease
    Sarles, Harry E., Jr.
    Whitney, Annette E.
    Kuten, Samantha A.
    Van Anglen, Lucinda J.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S643 - S644
  • [10] CORRELATION OF VEDOLIZUMAB TROUGH LEVELS WITH CLINICAL AND BIOCHEMICAL MARKERS IN INFLAMMATORY BOWEL DISEASE
    Tamilarasan, Aravind Gokul
    Guerrero, Antonio
    Arias, Laura
    Burns, Megan
    Arkir, Zehra
    Irving, Peter
    [J]. GUT, 2019, 68 : A98 - A99
12345